In a bid to bolster its health diagnostic business, Thermo Fisher Scientific has agreed to pay US$11.5 B to acquire Qiagen, a global provider of molecular diagnostics and sample preparation technologies. The deal combines Thermo Fisher’s specialty diagnostics capabilities with Qiagen’s 500 core products in molecular testing applications focused on infectious disease and other growth opportunities. The deal is expected to close in the first half of 2021.